Anti-IL-38 therapy has been reported to restore host anti-tumour immunity by counteracting tumour-induced suppression of early immune activation in mouse models of breast cancer and melanoma (32), emphasising its potential in precision oncology. The gene discussed is IL1F10; the disease is neoplasm.